YOKNEAM, Israel -- Arbel Medical, an Israeli start-up developing the next generation of medical equipment for removing tumors by freezing (cryotherapy), has raised $4.5 million of capital in its second round, led by the Giza Venture Capital fund.

The Docor International investment company, of the Van Leer group, invested $1 million, joining the other Arbel investors who include Giza Venture Capital, Ofer High Tech, the Bridge Investment Fund from theUSA, TRD and Fattal. Dr. Alon Dumanis, CEO of Docor, will be appointed as a member of the Board of Directors of Arbel Medical.

Arbel Medical works in the field of minimal- invasive treatments. The company is developing next generation medical devices for removing tumors by freezing (cryotherapy). Cryotherapy is considered the most promising minimally invasive technique for removing tumors, a market that, according to MedMarket Diligence, is expected to grow at a rate of 30% a year in the coming decade. Arbel Medical brings promising news to women's health treatments, a market worth billions of dollars. Quick and effective treatment using Arbel's innovative device can be carried out in clinics outside hospitals.

Arbel Medical was chosen as one of the three most promising start-ups inIsrael in 2007 by the Export Institute, the Israel Life Sciences Institute (ILSI) and LSA.

About Arbel Medical

Arbel Medical, established in 2006, is active in the field of minimal-invasive treatments. The company is developing next generation medical devices for removing tumors by freezing (cryotherapy). Among Arbel Medical's investors are Giza Venture Capital, which led the last capital raising round, the Ofer High Tech Group, the US-based Bridge Investment Fund, Docor International, TRD and Fattal.

About Docor International B.V

A leading investment group, Docor International B.V is part of the Van Leer Group Foundation. Docor invests in advanced technology-based companies with an Israeli presence, that make a significant contribution to the local economy. It focuses on companies in the life sciences, information technology and on industrial sectors with innovative technologies.

About Giza Venture Capital

Giza Venture Capital was established in 1992 and was one of the first Israeli investors specializing in early stage and seed investment. Giza manages around $500 million in four funds, and has invested in 87 companies with 32 exits to date. Giza focuses in the fields of communications, semi-conductors, software, IT, internet, new media, and life sciences, and has offices inTel Aviv and Singapore. For additional information: http://www.arbel-medical.com